Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty.

Autor:	Ranganath LR; Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool, UK.; Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Khedr M; Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool, UK., Norman BP; Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Hughes JH; Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Imrich R; Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Faculty of Medicine of Comenius University, Bratislava, Slovakia., Arnoux JB; Hôpital Necker-Enfants Malades, Paris Cedex 15, France., Olsson B; Garriguella AB, Ekerö, Sweden., Rudebeck M; OnPoint Science AB, Stockholm, Sweden., Gallagher JA; Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Bou-Gharios G; Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Jazyk:	angličtina
Zdroj:	Molecular genetics and metabolism reports [Mol Genet Metab Rep] 2024 May 24; Vol. 40, pp. 101097. Date of Electronic Publication: 2024 May 24 (Print Publication: 2024).
DOI:	10.1016/j.ymgmr.2024.101097
Abstrakt:	Background: Increased homogentisic acid (HGA) in alkaptonuria (AKU) causes severe arthritis. Nitisinone reduces the production of HGA, but whether it also decreases arthroplasty was examined in 237 AKU patients. Patients and Methods: Patients attending the United Kingdom National Alkaptonuria Centre (NAC) and the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) study were studied. Assessments included questionnaires eliciting details of arthroplasty. Nitisinone was administered from baseline, 2 mg in the NAC and 10 mg in SONIA 2. In SONIA 2, subgroups consisted of those with baseline arthroplasty on and not on nitisinone (BR + N+, BR + N-), as well as those without baseline arthroplasty on and not on nitisinone (BR-N+, BR-N-). Results: In the SONIA2 subgroups, new joint replacement (JR) probabilities after baseline were significantly different (BR + N+, BR + N-, BR-N+, BR-N-) (χ ² = 23.3, p < 0.001); mean (SD) was 3.8 (0.1) years in BR-N-, 3.7 (0.1) years in BR-N+, 3.4 (0.3) years in BR + N-, and 3.0 (0.3) years in BR + N+. Further, the BR + N- showed more JR than the BR-N- subgroup ( p < 0.01), while BR + N+ similarly showed more JR than the BR-N+ subgroup ( p < 0.001).In the NAC, the BR- group had a mean age of 51.6 ( 7.0) years at baseline but 57.7 (8.7) years at final follow up during nitisinone therapy and showed only 7 incident JR. The BR+ group had an age at baseline of 57.4 (8.5) years and had undergone 94 JRs at baseline. Conclusion: The incidence of arthroplasty was earlier and more frequent after the first JR and was not affected by nitisinone. Competing Interests: Lakshminarayan Ranganath received fees for lectures and consultations from Swedish Orphan Biovitrum (Sobi). Birgitta Olsson and Mattias Rudebeck are ex-Sobi employees. Milad Khedr, Brendan Norman, Juliette Hughes, Richard Imrich, Jean-Baptiste Arnoux, James Gallagher and George Bou-Gharios do not have anything to declare and have no conflicts to publication of this manuscript. (© 2024 The Authors. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu